MARSHALL EDWARDS ANNOUNCES PUBLICATION OF PRE-CLINICAL STUDIES IN PANCREATIC CANCER

Novogen Limited’s subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following announcement.

San Diego – 27 June, 2011 - Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitiser. The publication is now available on the Anti-Cancer Drugs website and scheduled to print in the August issue of the journal.

The studies, conducted in collaboration with lead author Ewan Tytler, Ph.D., at the University of Alabama at Birmingham Medical Center and the Yale University School of Medicine, detail the in vitro activity of triphendiol in pancreatic cancer cells as well as its in vivo activity in animal models of pancreatic cancer. In addition, both studies show that pre-treatment with triphendiol enhances the cytotoxic effect of gemcitabine, the standard-of-care chemotherapy currently used to treat advanced pancreatic cancer. An abstract of the publication, entitled "Triphendiol (NV-196), Development of a Novel Therapy for Pancreatic Cancer,” can be found at www.marshalledwardsinc.com/our-programs/scientific-publications.

In previous laboratory studies, triphendiol demonstrated anti-cancer activity against a broad range of tumour cell lines, including breast, colorectal and ovarian. Once administered, triphendiol is converted in vivo into an active metabolite called NV-143. In addition to being more active than triphendiol as a single agent, NV-143 appears to be superior in its ability to synergize with chemotherapy in pre-clinical studies. Marshall Edwards has completed the required pre-clinical studies of NV-143 necessary to complete an Investigational New Drug application, which it plans to submit to the US Food and Drug Administration next month.

"These studies add to our growing collection of data regarding the activity of our compounds and their potential ability to enhance the effects of current treatments," said Robert D Mass, MD, Chief Medical Officer of Marshall Edwards. "These data further support the clinical development strategy for our lead candidate NV-143, the primary metabolite of triphendiol, in combination with standard-of-care chemotherapy, while expanding the potential drug combinations we can consider in our randomised Phase II clinical trials."

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumour cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes triphendiol and lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344.
Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

About Novogen Limited

Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen has a consumer healthcare business, conducts research and development on oncology therapeutics through its 71.3 per cent owned subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its 80.7 per cent owned subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

Issued For: NOVOGEN LIMITED
Listings: ASX (CODE NRT), NASDAQ (CODE NVGN).
For Further Information: PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE COMMUNICATIONS, MARSHALL EDWARDS, INC. TEL +1 858-792-3729 http://www.marshalledwardsinc.com
Issued By: WESTBROOK COMMUNICATIONS
Contact: IAN WESTBROOK TEL (02) 9231 0922